bullish
Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"
301 Views01 Dec 2020 09:34
This article analyzed Harbour's core products, team, technology platforms, thoughts on valuation and the "hidden" value that is often easy to be ignored by investors.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (Dec.4)07 Dec 2020
- Pre-IPO New Horizon Health (NHH.HK) - Here Are the Concerns03 Dec 2020
- Livzon Pharmaceutical (000513.CH) - A Good Company that You Can't Afford Missing02 Dec 2020
- Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"01 Dec 2020
- China Healthcare Weekly (Nov.27)30 Nov 2020
- Pre-IPO Edding Group - Strong Core Products but Still Have Concerns26 Nov 2020
- 2021 High Conviction - Investment Opportunities in China Healthcare Industry23 Nov 2020
x